SG11201804204QA - Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer - Google Patents
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancerInfo
- Publication number
- SG11201804204QA SG11201804204QA SG11201804204QA SG11201804204QA SG11201804204QA SG 11201804204Q A SG11201804204Q A SG 11201804204QA SG 11201804204Q A SG11201804204Q A SG 11201804204QA SG 11201804204Q A SG11201804204Q A SG 11201804204QA SG 11201804204Q A SG11201804204Q A SG 11201804204QA
- Authority
- SG
- Singapore
- Prior art keywords
- genentech
- international
- dna
- san francisco
- way
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268149P | 2015-12-16 | 2015-12-16 | |
| US201662288832P | 2016-01-29 | 2016-01-29 | |
| US201662291248P | 2016-02-04 | 2016-02-04 | |
| PCT/US2016/067174 WO2017106647A1 (en) | 2015-12-16 | 2016-12-16 | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804204QA true SG11201804204QA (en) | 2018-06-28 |
Family
ID=59057647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804204QA SG11201804204QA (en) | 2015-12-16 | 2016-12-16 | Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10906918B2 (zh) |
| EP (2) | EP3978500B1 (zh) |
| CN (2) | CN108697713B (zh) |
| AU (3) | AU2016369528B2 (zh) |
| CA (1) | CA3008394A1 (zh) |
| DK (1) | DK3389662T3 (zh) |
| ES (2) | ES2972605T3 (zh) |
| HK (1) | HK1256363A1 (zh) |
| HR (1) | HRP20220227T1 (zh) |
| MY (1) | MY196817A (zh) |
| PL (2) | PL3389662T3 (zh) |
| SG (1) | SG11201804204QA (zh) |
| WO (1) | WO2017106647A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3389662T3 (da) | 2015-12-16 | 2022-02-28 | Genentech Inc | Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer |
| US10767006B2 (en) * | 2017-06-07 | 2020-09-08 | Medtronic, Inc. | Hydrogenation of tyrosine derived polyarylates |
| KR20210146290A (ko) * | 2019-02-12 | 2021-12-03 | 스미토모 다이니폰 파마 온콜로지, 인크. | 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
| GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DE69428764T2 (de) | 1993-12-24 | 2002-06-20 | Merck Patent Gmbh | Immunokonjugate |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| SK398A3 (en) | 1995-07-06 | 1998-07-08 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| RO121900B1 (ro) | 1996-04-12 | 2008-07-30 | Warner-Lambert Company | Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| PL340800A1 (en) | 1997-11-06 | 2001-02-26 | American Cyanamid Co | Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps |
| WO2000031048A1 (en) | 1998-11-19 | 2000-06-02 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases |
| GB2356630A (en) * | 1999-11-10 | 2001-05-30 | Merck & Co Inc | Intermediates used in the preparation of tetrahydronaphthyridine |
| KR20040024564A (ko) | 2001-07-12 | 2004-03-20 | 아베시아 리미티드 | 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법 |
| WO2009116069A2 (en) * | 2008-02-04 | 2009-09-24 | Ipca Laboratories Limited | Process for preparation of 1-(9h-carbazol-4-yloxy)-3-[[2-(2- methoxyphenoxy) ethyl] amino]-2-propanol |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| MX2012002059A (es) * | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
| JP5585257B2 (ja) * | 2010-07-16 | 2014-09-10 | 株式会社リコー | 画像形成装置、機器システム、プログラム管理方法、プログラム |
| JP5998145B2 (ja) * | 2010-10-01 | 2016-09-28 | ノバルティス アーゲー | ピリミジン誘導体の製造プロセス |
| TWI441824B (zh) * | 2010-12-16 | 2014-06-21 | Hoffmann La Roche | 三環ｐｉ３ｋ抑制劑化合物及其使用方法 |
| ES2721302T3 (es) * | 2013-10-04 | 2019-07-30 | Univ Basel | Inhibidores de PI3k y mTOR conformacionalmente restringidos |
| DK3389662T3 (da) | 2015-12-16 | 2022-02-28 | Genentech Inc | Fremgangsmåde til fremstilling af tricykliske PI3K-inhibitorforbindelser og fremgangsmåder til anvendelse af disse til behandling af cancer |
-
2016
- 2016-12-16 DK DK16876773.9T patent/DK3389662T3/da active
- 2016-12-16 US US15/780,328 patent/US10906918B2/en active Active
- 2016-12-16 ES ES21204490T patent/ES2972605T3/es active Active
- 2016-12-16 EP EP21204490.3A patent/EP3978500B1/en active Active
- 2016-12-16 CN CN201680073496.2A patent/CN108697713B/zh active Active
- 2016-12-16 EP EP16876773.9A patent/EP3389662B1/en active Active
- 2016-12-16 ES ES16876773T patent/ES2907574T3/es active Active
- 2016-12-16 HR HRP20220227TT patent/HRP20220227T1/hr unknown
- 2016-12-16 AU AU2016369528A patent/AU2016369528B2/en active Active
- 2016-12-16 CN CN202111170407.5A patent/CN113999249A/zh active Pending
- 2016-12-16 SG SG11201804204QA patent/SG11201804204QA/en unknown
- 2016-12-16 WO PCT/US2016/067174 patent/WO2017106647A1/en active Application Filing
- 2016-12-16 PL PL16876773T patent/PL3389662T3/pl unknown
- 2016-12-16 MY MYPI2018702031A patent/MY196817A/en unknown
- 2016-12-16 PL PL21204490.3T patent/PL3978500T3/pl unknown
- 2016-12-16 CA CA3008394A patent/CA3008394A1/en active Pending
-
2018
- 2018-12-03 HK HK18115452.9A patent/HK1256363A1/zh unknown
-
2020
- 2020-12-08 US US17/115,095 patent/US11643421B2/en active Active
-
2021
- 2021-07-05 AU AU2021204704A patent/AU2021204704B2/en active Active
-
2023
- 2023-03-24 US US18/189,623 patent/US20230242550A1/en active Pending
- 2023-06-29 AU AU2023204160A patent/AU2023204160A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017106647A1 (en) | 2017-06-22 |
| PL3389662T3 (pl) | 2022-04-04 |
| HRP20220227T1 (hr) | 2022-04-29 |
| EP3389662A1 (en) | 2018-10-24 |
| AU2016369528B2 (en) | 2021-04-22 |
| ES2907574T3 (es) | 2022-04-25 |
| CA3008394A1 (en) | 2017-06-22 |
| EP3389662B1 (en) | 2021-12-01 |
| HK1256363A1 (zh) | 2019-09-20 |
| MY196817A (en) | 2023-05-03 |
| PL3978500T3 (pl) | 2024-03-11 |
| US10906918B2 (en) | 2021-02-02 |
| ES2972605T3 (es) | 2024-06-13 |
| EP3978500C0 (en) | 2023-11-22 |
| EP3978500A1 (en) | 2022-04-06 |
| US20180354970A1 (en) | 2018-12-13 |
| CN108697713A (zh) | 2018-10-23 |
| US11643421B2 (en) | 2023-05-09 |
| CN113999249A (zh) | 2022-02-01 |
| AU2021204704A1 (en) | 2021-08-05 |
| EP3389662A4 (en) | 2019-05-08 |
| AU2021204704B2 (en) | 2023-04-06 |
| AU2016369528A1 (en) | 2018-06-07 |
| DK3389662T3 (da) | 2022-02-28 |
| US20210253599A1 (en) | 2021-08-19 |
| AU2023204160A1 (en) | 2023-07-20 |
| EP3978500B1 (en) | 2023-11-22 |
| US20230242550A1 (en) | 2023-08-03 |
| CN108697713B (zh) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
| SG11201900043TA (en) | Antibody formulations |